First reported by bsky
Medicare Launches $50/Month GLP-1 Weight-Loss Drug Trial: What Beneficiaries Need to Know
CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications
By
Wed, 07/01/2026 - 09:55
3d ago
Source
cms.govCMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medicationscms.govCMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications Eligible Medicare beneficiaries may now get certain GLP-1 medications for $50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program.
You might also wanna read
Medicare Launches $50/Month GLP-1 Weight-Loss Drug Trial: What Beneficiaries Need to Know
Starting this week, the federal government launched a new trial program called Medicare GLP-1 Bridge, offering certain GLP-1 agonist medicat
medpagetoday.com·1d ago
Medicare begins covering weight-loss medications: who qualifies and how the new program will work
EL PAÍS·3d ago
:max_bytes(150000):strip_icc()/glp1419-05262026-3b927deb18854c46a35a2eb6f7ccec4a.jpg)
Medicare Will Soon Offer Low-Cost GLP-1 Weight-Loss Drugs. What You Need to Know
people.com·1mo ago
:max_bytes(150000):strip_icc()/GLP1-Now-Affordable-052926-1d50af52042b44b79fc71edef280243d.jpg)
This Mom Saw Success on GLP-1s, but Cost Was 'Becoming Prohibitive.' On July 1, Medicare's $50 Pricing Will Change That
people.com·1mo ago
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p
theverge.com·29d ago
GLP-1 weight loss drugs reduce food spending, creating a $6.5 billion challenge for major grocery retailers
The article discusses how GLP-1 weight loss drugs like tirzepatide are significantly impacting consumer spending on food, creating a $6.5 bi
bit.ly·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.